Cell therapy for advanced liver cancer with GPC3 protein
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your liver cancer is advanced (Stage B or C) and cannot be removed by surgery, or has come back after surgery or other treatments.
- You have already tried at least one type of drug treatment for your liver cancer (like immunotherapy or targeted pills) and it didn't work.
- Your liver function is fairly good (Child-Pugh score A or B7) and you have never had hepatic encephalopathy (confusion from liver disease).
- You are in good general health (able to do daily activities) and expected to live at least 3 more months.
- You have at least one tumor that can be seen on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to better find and attack liver cancer cells. It is for people whose liver cancer has returned or spread and cannot be removed with surgery.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack liver cancer cells with a specific protein (GPC3). The goal is to see if this treatment can help people with advanced liver cancer that hasn't responded to other treatments.
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.